



**PHARMA 1 HUMANITAS HOLDINGS LTD PROVIDES SOLUTIONS TO HELP PATIENTS AND HEALTHCARE SYSTEM IN ORDER TO MAKE BETTER HEALTH AND WELL-BEING DECISIONS BY SOURCING TESTS AND SCREENINGS FROM REPUTABLE WORLDWIDE FACTORIES THAT ALREADY HAVE THE STOCKS OF THE ITEMS EX-WORKS. THESE SCREENINGS AND TESTS CAN BE HELPFUL IF YOU'RE LOOKING FOR INFORMATION ON CANCER RISK, CANCER TREATMENT, PRENATAL CARE, HAEMATOLOGY, AND ONCOLOGY HEALTH. PROVIDERS OF TEST KITS FOR MOLECULAR GENETIC DIAGNOSTICS AT EVERY STEP. OUR PRIMARY FOCUS IS ON CREATING CUTTING-EDGE DIAGNOSTIC EQUIPMENT FOR THE DIAGNOSIS OF GENETIC DISORDERS IN HUMANS. MEDICAL FACILITIES MAY USE PRODUCTS THAT ARE MEANT FOR DIAGNOSTIC USAGE SINCE THEY ARE CLASSIFIED AS CERTIFIED AND PATENTED WITH ALL INTERNATIONAL STANDARDS & REQUIREMENTS.**





**THIS INNOVATIVE EQUIPMENT DISTRIBUTED BY PHARMA1HUMANITAS HOLDINGS LTD, IS USED TO MAP AND VISUALIZE WITH FLUORESCENT MARKERS SPECIFIC DNA SEQUENCES IN CELLS OR TISSUES, ALLOWING TO IDENTIFY GENETIC ANOMALIES (FUSIONS, AMPLIFICATIONS OR GENE DELETIONS) UNDERLYING TUMORS AND OTHER PATHOLOGIES. THANKS TO THE RAPID HYBRIDIZATION TECHNOLOGY, INCUBATION REQUIRES ONLY ABOUT 2 HOURS INSTEAD OF DAYS, PROVIDING DIAGNOSTIC RESULTS IN MUCH SHORTER TIMES**



- ✓ **IMPORTANCE OF EXTERNAL QUALITY ASSESSMENT SAMPLES**
- ✓ **MEDICAL DISEASE TESTS**
- ✓ **VACUUM TUBES**
- ✓ **REAGENTS**
- ✓ **DISPOSABLES DISEASE DIAGNOSTIC ITEMS**
- ✓ **SOFTWARE**
- ✓ **LABORATORY EQUIPMENT**



# **DNA/RNA DISEASE DIAGNOSTIC EQUIPMENT: LIST OF DISEASES DETECTABLE WITH OUR INSTRUMENTS**

## **I. ONCOLOGICAL DISEASE ENTITIES**

### **A. SOLID TISSUE MALIGNANCIES**

- . GASTRIC CARCINOMA  
(NEOPLASTIC DISEASE OF THE STOMACH)**
- . CERVICAL CARCINOMA  
(NEOPLASTIC DISEASE OF THE CERVIX UTERI)**
- . PULMONARY NON-SMALL CELL CARCINOMA  
(NON-SMALL CELL LUNG CARCINOMA)**
- . MAMMARY GLAND CARCINOMA  
(BREAST CARCINOMA)**
- . URINARY VESICAL CARCINOMA  
(BLADDER CARCINOMA)**
- . CEREBRAL NEOPLASTIC PROLIFERATION  
(BRAIN NEOPLASM)**
- . SOFT TISSUE SARCOMATOUS LESION  
(SOFT TISSUE CANCER)**
- . PERIPHERAL NEUROGENIC NEOPLASTIC MASS  
(PERIPHERAL NERVE TISSUE TUMOR)**
- . CARTILAGINOUS NEOPLASTIC GROWTH  
(CARTILAGE TUMOR)**
- . THYROID GLAND NEOPLASM  
(THYROID CARCINOMA)**
- . FIBROHISTIOCYTIC LESION**

### **B. GENITOURINARY & VASCULAR NEOPLASMS**

- . PROSTATIC ADENOCARCINOMA  
(PROSTATE CARCINOMA)**
- . RENAL TUBULAR EPITHELIAL CARCINOMA  
(RENAL CELL CARCINOMA)**
- . RENAL AND ANGIOGENIC NEOPLASTIC MASS  
(KIDNEY & VASCULAR TUMOR)-----**





# **DNA/RNA DISEASE DIAGNOSTIC EQUIPMENT: LIST OF DISEASES DETECTABLE WITH OUR INSTRUMENTS**

## **II. HEMATOPOIETIC & LYMPHOID MALIGNANCIES**

- . PERSISTENT LYMPHOID MONONUCLEAR HEMATOPOIETIC NEOPLASM  
(CHRONIC LYMPHOCYTIC LEUKEMIA – CLL)**
- . SUDDEN-ONSET MYELOGENOUS HEMATOLOGICAL MALIGNANCY,  
NON-PROMYELOCYTIC SUBTYPE  
(ACUTE MYELOID LEUKEMIA, NON-ACUTE PROMYELOCYTIC LEUKEMIA – AML [NON-APL])**
- . PERSISTENT MYELOGENOUS HEMATOLOGICAL MALIGNANCY  
(CHRONIC MYELOID LEUKEMIA – CML)**
- . SUDDEN-ONSET LYMPHOBLASTIC HEMATOLOGICAL MALIGNANCY  
(ACUTE LYMPHOBLASTIC LEUKEMIA – ALL)**
- . MULTIFOCAL PLASMA CELL NEOPLASTIC DISORDER  
(MULTIPLE MYELOMA – MM)**
- . MONOCLONAL IMMUNOGLOBULIN-SECRETING PLASMA CELL DYSCRASIA  
(PLASMA CELL MYELOMA – PCM)**
- . MYELOID LINEAGE MATURATION DISORDER  
(MYELOYDYSPLASTIC SYNDROME – MDS)**
- . BONE-MARROW APLASIA SYNDROME  
(APLASTIC ANEMIA)**
- . LYMPHATIC SYSTEM MALIGNANT PROLIFERATION  
(LYMPHOMA)**
- . PERIPHERAL B-CELL LYMPHOPROLIFERATIVE DISORDER  
(NON-HODGKIN LYMPHOMA)**
- . HEMATOPOIETIC STEM CELL HYPERPROLIFERATIVE DISORDER  
(MYELOPROLIFERATIVE DISEASE)**
- . EXTRASKELETAL MUCOID CARTILAGINOUS MALIGNANCY  
(EXTRASKELETAL MYXOID CHONDROSARCOMA – EMC)**

# HOSPITAL






FISH



HOSPITAL



**We provide turnkey project for construction a laboratory that conducts sophisticated molecular diagnostics for the main types of myeloid and lymphoid leukaemia as well as multiple myelosis is another aspect of Pharma1humanitas' consulting service. novel molecular classifiers for the diagnosis, prognosis, and monitoring of the therapy response are identified as a result of high-resolution technologies, as are potential novel therapeutic targets. In close cooperation with the relevant clinical reference research groups, working groups of Italian scientists and researchers will oversee the laboratory's diagnostic-molecular activity and translational studies pertaining to various haematological, tumour, Alzheimer's, and oncology diseases.**



**PHARMA 1 HUMANITAS HOLDINGS LTD IS A RAPIDLY  
GROWING LEADING IN THE FIELD OF GENETIC TESTING,  
MOLECULAR BIOLOGY CONSULTANCY,HOSPITAL  
TRANSFUSION EQUIPMENT.  
WE OFFERING QUICK AND AFFORDABLE DIAGNOSTIC  
OPTIONS FOR A WIDE RANGE OF ILLNESSES.**





**PHARMA 1 HUMANITAS HOLDINGS LTD IS A RAPIDLY GROWING LEADING IN THE FIELD OF GENETIC TESTING, OFFERING QUICK AND AFFORDABLE DIAGNOSTIC OPTIONS FOR A WIDE RANGE OF ILLNESSES.**



**FLUORESCENCE IN SITU  
HYBRIDIZATION TEST SUPPLIED ALL  
EQUIPMENT, INSTRUMENTS AND  
TEST FROM THE DISTRIBUTOR'S:  
PHARMA1HUMANITAS HOLDIGS LTD**




# **PHARMA 1 HUMANITAS HEMATOLOGY,ONCOLOGY AND TUMOR TEST**



**FLUORESCENCE IN SITU  
HYBRIDIZATION TEST SUPPLIED ALL  
EQUIPMENT,INSTRUMENTS AND  
TEST FROM THE DISTRIBUTOR'S:  
PHARMA1HUMANITAS HOLDIGS LTD**



# **PHARMA 1 HUMANITAS HEMATOLOGY,ONCOLOGY AND TUMOR TEST**



**FLUORESCENCE IN SITU HYBRIDIZATION  
TEST SUPPLIED ALL  
EQUIPMENT,INSTRUMENTS AND  
TEST FROM THE DISTRIBUTOR'S:  
PHARMA1HUMANITAS HOLDIGS LTD**





# **PHARMA 1 HUMANITAS HEMATOLOGY,ONCOLOGY AND TUMOR TEST KIT**



**FLUORESCENCE IN SITU  
HYBRIDIZATION TEST SUPPLIED ALL  
EQUIPMENT,INSTRUMENTS AND  
TEST FROM THE DISTRIBUTOR'S:  
PHARMA1HUMANITAS HOLDIGS LTD**



**FOR GENETIC TESTS AVAILABLE FOR SALE SUPPLIED BY FACTORIES, IT MAY BE ACCOMPANIED BY THE MADE IN ITALY TOOL UNDER CONSTRUCTION IN THE FUTURE WITH A NEW PATENT TO BE BUILT. THE GENETIC TESTS ARE ALREADY PATENTED AND ISO -CE CERTIFIED AVAILABLE TO SUPPLY EX-WORKS FROM INTERNATIONAL FACTORIES.**

**THIS TEST FOR THE CLINICAL ANALYSIS OF DNA, RNA, CHROMOSOMES, PROTEINS,**

**METABOLITES OR OTHER GENE PRODUCTS TO HIGHLIGHT GENOTYPES, MUTATIONS, PHENOTYPES OR KARYOTYPES CORRELATED**

**OR NOT WITH HUMAN HERITABLE DISEASES. THIS DEFINITION INCLUDES PRENATAL,**

**NEONATAL AND CARRIER SCREENING, AS WELL AS TESTS ON FAMILIES AT RISK. THE RESULTS OF THESE INVESTIGATIONS CAN BE APPLIED TO THE DIAGNOSIS AND PROGNOSIS OF HEREDITARY DISEASES, TO THE PREDICTION OF**

**DISEASE RISK, TO THE IDENTIFICATION OF HEALTHY CARRIERS, TO PHENOTYPE-GENOTYPE CORRELATIONS. FURTHERMORE, WHILE MAINTAINING THE DEFINITION OF GENETIC TESTING JUST DESCRIBED, THIS**

**DOCUMENT CONSIDERS, IN ADDITION TO THE TESTS USED FOR INDIVIDUAL IDENTIFICATION FOR MEDICOLEGAL REASONS, ALSO THE TESTS FOR THE CLINICAL ANALYSIS OF DNA, RNA, CHROMOSOMES, PROTEINS OR OTHER**

**GENE PRODUCTS TO HIGHLIGHT GENOTYPES, MUTATIONS, PHENOTYPES OR KARYOTYPES RELATED TO HUMAN PATHOLOGIES ARISING ON SOMATIC CELLS.**



**ON THE OTHER HAND, TESTS PERFORMED FOR RESEARCH PURPOSES ONLY ARE EXCLUDED.**





**Fluorescence in situ hybridization** it is a test that "maps" the genetic material in human cells, including specific genes or portions of genes. Because this type of innovative test can detect genetic abnormalities associated with cancer, it's useful for diagnosing some types of the disease. When the type of cancer has previously been diagnosed, a Fluorescence in situ hybridization test also may provide additional information to help predict a patient's outcome and whether he or she is likely to respond to chemotherapy medicine.





**METHODS IMPROVE PROCESS EFFICIENCY AND AUTOMATE REPORTING TO ADDRESS ISSUES THAT LABORATORIES ENCOUNTER.**

**AT PHARMA1HUMANITAS HOLDINGS LTD, WE WANT TO SUPPORT LABS IN SCALING UP COMPREHENSIVE GENOMIC PROFILING (CGP, WHICH IS) AND MAKING IT ACCESSIBLE TO A LARGER AUDIENCE. IN ORDER TO UNDERTAKE NEXT-GENERATION SEQUENCING (NGS), WHICH IS AN EMERGING TECHNOLOGY THAT MAY DETERMINE DNA/RNA SEQUENCES FOR ENTIRE GENOMES OR SPECIFIC REGIONS OF INTEREST AT A SIGNIFICANTLY CHEAPER COST THAN TRADITIONAL SANGER SEQUENCING, WE OFFER A DEPENDABLE AND COMPREHENSIVE ENRICHMENT AND LIBRARY PREP SOLUTION. OUR PROGRAMMI CAN GENERATE A STRAIGHTFORWARD CLINICALLY ACTIONABLE REPORT FOR THE ONCOLOGIST OR GIVE ACCESS TO THE DATA IN ITS ENTIRETY. PHARMA1HUMITAS HOLDINGS LTD PROVIDE TO OUR CUSTOMERS AND HOSPITALS WITH A WAY TO VISUALIZE AND MAP THE GENETIC MATERIAL IN AN INDIVIDUAL'S CELLS, INCLUDING SPECIFIC GENES OR PORTIONS OF GENES. THIS MAY BE USED FOR UNDERSTANDING A VARIETY OF CHROMOSOMAL ABNORMALITIES AND OTHER GENETIC MUTATIONS**










## **PHARMA1HUMANITAS BLOOD TRANSFUSION KIT**



## **PHARMA1HUMANITAS BLOOD TUBE KIT**



# **PHARMA1HUMANITAS SYRINGE**







[pharma1humanitas@gmail.com](mailto:pharma1humanitas@gmail.com)

[www.pharma1humanitas.com](http://www.pharma1humanitas.com)

